Progress of poly (adenosine diphosphate-ribose) polymerase inhibitors in treatment of colorectal cancer
10.3760/cma.j.cn115355-20210618-00266
- VernacularTitle:聚二磷酸腺苷核糖聚合酶抑制剂在结直肠癌治疗中的研究进展
- Author:
Zhiqin CHEN
1
;
Haifei SONG
;
Yong GAO
;
Ming QUAN
Author Information
1. 同济大学附属东方医院肿瘤科，上海 200123
- Keywords:
Colorectal neoplasms;
PARP inhibitor;
Homologous recombination deficiency;
Treatment outcome
- From:
Cancer Research and Clinic
2022;34(4):310-313
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is one of the most common malignant tumors, and its morbidity and mortality increase year by year. In recent years, some patients with colorectal cancer have benefited from precision targeted therapies, but the overall prognosis is still unsatisfactory. Treatment of homologous recombination deficiency represented by BRCA1/2 has become a hot research direction at present. With the wide application and exact curative effect of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, breast cancer, pancreatic cancer and other malignant tumors, PARP inhibitors are also gradually being used in colorectal cancer. This review summarizes the current research progress of PARP inhibitors in treatment of colorectal cancer.
